{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:27:56Z","timestamp":1792700876003,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016250","name":"New York Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.npep.2026.102605","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:36:23Z","timestamp":1772696183000},"page":"102605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Revisited case for intranasal neuropeptide Y based therapeutics: From preclinical to clinical"],"prefix":"10.1016","volume":"117","author":[{"given":"Esther Louise","family":"Sabban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arax","family":"Tanelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.npep.2026.102605_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091870","article-title":"Nose-to-brain delivery of therapeutic peptides as nasal aerosols","volume":"14","author":"Alabsi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0010","first-page":"207","article-title":"Cerebrospinal fluid neuropeptide Y in Alzheimer\u2019s disease","volume":"30","author":"Alom","year":"1990","journal-title":"Eur. Neurol."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/14728222.2024.2342524","article-title":"Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus","volume":"28","author":"Arrabal-G\u00f3mez","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.npep.2026.102605_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2023.102388","article-title":"Cross talk about the role of Neuropeptide Y in CNS disorders and diseases","volume":"102","author":"Bale","year":"2023","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0006-8993(00)02285-X","article-title":"Behavioral characterization of neuropeptide Y knockout mice","volume":"868","author":"Bannon","year":"2000","journal-title":"Brain Res."},{"issue":"23","key":"10.1016\/j.npep.2026.102605_bb0030","doi-asserted-by":"crossref","first-page":"8927","DOI":"10.1523\/JNEUROSCI.17-23-08927.1997","article-title":"Knock-out mice reveal a critical antiepileptic role for neuropeptide Y","volume":"17","author":"Baraban","year":"1997","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.npep.2026.102605_bb0035","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1152\/jappl.1992.73.5.1867","article-title":"Barnes PJ: neuropeptide Y is a vasoconstrictor in human nasal mucosa","volume":"73","author":"Baraniuk","year":"1992","journal-title":"J. Appl. Physiol. (1985)"},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0040","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.410200303","article-title":"Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer\u2019s disease","volume":"20","author":"Beal","year":"1986","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.npep.2026.102605_bb0045","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400087R","article-title":"Long-term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co-administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus","volume":"38","author":"Beltran-Casanueva","year":"2024","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.npep.2026.102605_bb0050","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: a transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.npep.2026.102605_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.820210","article-title":"Intranasal delivery of Galanin 2 and neuropeptide Y1 agonists enhanced spatial memory performance and neuronal precursor cells proliferation in the dorsal hippocampus in rats","volume":"13","author":"Borroto-Escuela","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"22","key":"10.1016\/j.npep.2026.102605_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223629","article-title":"Intranasal peptide therapeutics: a promising avenue for overcoming the challenges of traditional CNS drug development","volume":"11","author":"Bose","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0065","first-page":"34","article-title":"Gender differences in trauma and posttraumatic stress disorder","volume":"5","author":"Breslau","year":"2002","journal-title":"J. Gend. Specif. Med."},{"issue":"2","key":"10.1016\/j.npep.2026.102605_bb0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tips.2006.12.003","article-title":"Neuropeptide tyrosine and pain","volume":"28","author":"Brumovsky","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0169-328X(98)00137-5","article-title":"Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment","volume":"59","author":"Caberlotto","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.npep.2026.102605_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.840120","article-title":"Genetic variants associated with resilience in human and animal studies","volume":"13","author":"Cahill","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"5 Pt 1","key":"10.1016\/j.npep.2026.102605_bb0085","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1164\/ajrccm.160.5.9902102","article-title":"Functional effects of neuropeptide Y receptors on blood flow and nitric oxide levels in the human nose","volume":"160","author":"Cervin","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.npep.2026.102605_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.580378","article-title":"Neuropeptide Y Is an immunomodulatory factor: direct and indirect","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.npep.2026.102605_bb0095","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/npp.2011.230","article-title":"The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder","volume":"37","author":"Cohen","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.euroneuro.2017.11.006","article-title":"Neuropeptide S in the basolateral amygdala mediates an adaptive behavioral stress response in a rat model of posttraumatic stress disorder by increasing the expression of BDNF and the neuropeptide YY1 receptor","volume":"28","author":"Cohen","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.npep.2026.102605_bb0105","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000323468","article-title":"Neuroprotective effect of neuropeptide Y against beta-amyloid 25\u201335 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production","volume":"8","author":"Croce","year":"2011","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.npep.2026.102605_bb0110","article-title":"beta-Cyclodextrin-crosslinked synthetic neuropeptide Y-based nanosponges in epilepsy by contributing GABAergic signal","volume":"45","author":"Desai","year":"2022","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0115","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.npep.2026.102605_bb0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.euroneuro.2009.09.006","article-title":"Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression","volume":"20","author":"Domschke","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0125","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41598-021-82339-5","article-title":"Pereira de Almeida L: Neuropeptide Y (NPY) intranasal delivery alleviates Machado-Joseph disease","volume":"11","author":"Duarte-Neves","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.npep.2026.102605_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.nbd.2016.07.022","article-title":"Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases","volume":"95","author":"Duarte-Neves","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.npep.2026.102605_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108623","article-title":"CB1 receptor neutral antagonist treatment epigenetically increases neuropeptide Y expression and decreases alcohol drinking","volume":"195","author":"Dulman","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2026.102605_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ynstr.2014.09.007","article-title":"Targeting the neuropeptide Y system in stress-related psychiatric disorders","volume":"1","author":"Enman","year":"2015","journal-title":"Neurobiol. Stress"},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apha.12445","article-title":"The homeostatic role of neuropeptide Y in immune function and its impact on mood and behavior","volume":"213","author":"Farzi","year":"2015","journal-title":"Acta Physiol. (Oxford)"},{"key":"10.1016\/j.npep.2026.102605_bb0150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.expneurol.2018.01.001","article-title":"Activation of NPY-Y2 receptors ameliorates disease pathology in the R6\/2 mouse and PC12 cell models of Huntington\u2019s disease","volume":"302","author":"Fatoba","year":"2018","journal-title":"Exp. Neurol."},{"issue":"53","key":"10.1016\/j.npep.2026.102605_bb0155","doi-asserted-by":"crossref","first-page":"41921","DOI":"10.1074\/jbc.M110.164020","article-title":"Neuropeptide Y modulation of interleukin-1beta (IL-1beta)-induced nitric oxide production in microglia","volume":"285","author":"Ferreira","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1471-4159.2011.07541.x","article-title":"Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility","volume":"120","author":"Ferreira","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.npep.2026.102605_bb0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brainres.2009.02.033","article-title":"Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: involvement of NPY Y1 receptors","volume":"1266","author":"Goyal","year":"2009","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0170","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0306-4530(02)00038-0","article-title":"NPY attenuates positive cortical DC-potential shift upon food intake in man","volume":"28","author":"Hallschmid","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0031-9384(04)00349-X","article-title":"Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man","volume":"83","author":"Hallschmid","year":"2004","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.npep.2004.05.002","article-title":"The NPY system in stress, anxiety and depression","volume":"38","author":"Heilig","year":"2004","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/REVNEURO.2002.13.1.85","article-title":"Brain neuropeptide Y (NPY) in stress and alcohol dependence","volume":"13","author":"Heilig","year":"2002","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.npep.2026.102605_bb0190","doi-asserted-by":"crossref","first-page":"1341295","DOI":"10.3389\/fnagi.2023.1341295","article-title":"Research progress in brain-targeted nasal drug delivery","volume":"15","author":"Huang","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0195","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acsptsci.5c00082","article-title":"Intranasal application of peptides modulating the neuropeptide Y system","volume":"8","author":"J\u00fclke","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102605_bb0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0006-8993(98)00076-6","article-title":"Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13\u201336 microinjected into vicinity of locus coeruleus in rats","volume":"788","author":"Kask","year":"1998","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0205","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0149-7634(01)00066-5","article-title":"The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y","volume":"26","author":"Kask","year":"2002","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.npep.2026.102605_bb0210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neulet.2016.11.061","article-title":"Neuropeptide Y, resilience, and PTSD therapeutics","volume":"649","author":"Kautz","year":"2017","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0215","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0091-6749(96)70095-7","article-title":"Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients","volume":"98","author":"Lacroix","year":"1996","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.npep.2026.102605_bb0220","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/j.1476-5381.1996.tb15647.x","article-title":"Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects","volume":"118","author":"Lacroix","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.npep.2026.102605_bb0225","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1210\/en.2014-1192","article-title":"Early intervention with Intransala NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats","volume":"155","author":"Laukova","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.npep.2026.102605_bb0230","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3389\/fnins.2019.00869","article-title":"Roles of neuropeptide Y in neurodegenerative and neuroimmune diseases","volume":"13","author":"Li","year":"2019","journal-title":"Front. Neurosci."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0235","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/archgenpsychiatry.2010.23","article-title":"Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques","volume":"67","author":"Lindell","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.npep.2026.102605_bb0240","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/ijnp\/pyaa054","article-title":"A randomized controlled trial of intranasal neuropeptide Y in patients with major depressive disorder","volume":"23","author":"Math\u00e9","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.npep.2026.102605_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107804","article-title":"Neuropeptide Y and cannabinoids interaction in the amygdala after exposure to shock and reminders model of PTSD","volume":"162","author":"Maymon","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.npep.2026.102605_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2013.31","article-title":"Allele-specific programming of Npy and epigenetic effects of physical activity in a genetic model of depression","volume":"3","author":"Melas","year":"2013","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0255","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0031-6997(24)01352-8","article-title":"XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors","volume":"50","author":"Michel","year":"1998","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.npep.2026.102605_bb0260","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/archgenpsychiatry.2010.197","article-title":"Emotion processing, major depression, and functional genetic variation of neuropeptide Y","volume":"68","author":"Mickey","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.npep.2026.102605_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061297","article-title":"Galanin and neuropeptide Y interaction enhances proliferation of granule precursor cells and expression of neuroprotective factors in the rat hippocampus with consequent augmented spatial memory","volume":"10","author":"Mirchandani-Duque","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.npep.2026.102605_bb0270","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0006-3223(02)01319-7","article-title":"Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report","volume":"52","author":"Morgan","year":"2002","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0275","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00006842-200105000-00010","article-title":"Relationship among plasma cortisol, catecholamines, neuropeptide Y, and human performance during exposure to uncontrollable stress","volume":"63","author":"Morgan","year":"2001","journal-title":"Psychosom. Med."},{"issue":"9","key":"10.1016\/j.npep.2026.102605_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/biom10091248","article-title":"Sex differences in the neuropeptide Y system and implications for stress related disorders","volume":"10","author":"Nahvi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.npep.2026.102605_bb0285","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnbeh.2019.00017","article-title":"Single prolonged stress as a prospective model for posttraumatic stress disorder in females","volume":"13","author":"Nahvi","year":"2019","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.npep.2026.102605_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.705579","article-title":"Intranasal neuropeptide Y as a potential therapeutic for depressive behavior in the rodent single prolonged stress model in females","volume":"15","author":"Nahvi","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.npep.2026.102605_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2016.05.035","article-title":"Evidence for the involvement of neuropeptide Y in the antidepressant effect of imipramine in type 2 diabetes","volume":"1646","author":"Nakhate","year":"2016","journal-title":"Brain Res."},{"issue":"12","key":"10.1016\/j.npep.2026.102605_bb0300","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1021\/acsptsci.4c00333","article-title":"Neuropeptide Y and Pain: insights from brain research","volume":"7","author":"Nelson","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0305","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/joim.20118","article-title":"The pharmacotherapeutic potential of neuropeptide Y for chronic pain","volume":"298","author":"Nie","year":"2025","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0310","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0196-9781(96)00013-7","article-title":"Differences in the neuropeptide Y-like immunoreactivity of the plasma and platelets of human volunteers and depressed patients","volume":"17","author":"Nilsson","year":"1996","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0315","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nyas.14172","article-title":"Preclinical findings on the potential of intranasal neuropeptide Y for treating hyperarousal features of PTSD","volume":"1455","author":"Nwokafor","year":"2019","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.npep.2026.102605_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2019.102001","article-title":"Activation of NPY receptor subtype 1 by [D-His(26)]NPY is sufficient to prevent development of anxiety and depressive like effects in the single prolonged stress rodent model of PTSD","volume":"80","author":"Nwokafor","year":"2020","journal-title":"Neuropeptides"},{"issue":"9","key":"10.1016\/j.npep.2026.102605_bb0325","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2174\/1570159X19666210906120302","article-title":"Neuroprotective Effects of Neuropeptide Y against neurodegenerative disease","volume":"20","author":"Pain","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.npep.2026.102605_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2025.102583","article-title":"Neuropeptide Y at the crossroads of neurodegeneration: mechanistic insights and emerging therapeutic strategies","volume":"115","author":"Palanivel","year":"2026","journal-title":"Neuropeptides"},{"issue":"9","key":"10.1016\/j.npep.2026.102605_bb0335","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.npp.1300705","article-title":"Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors","volume":"30","author":"Primeaux","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.npep.2026.102605_bb0340","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0006-3223(99)00185-7","article-title":"Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD","volume":"47","author":"Rasmusson","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2026.102605_bb0345","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/epi.18649","article-title":"Nanoparticle-encapsulated neuropeptide Y provides robust seizure protection in SCN1A-derived epilepsy","volume":"67","author":"Reed","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.npep.2026.102605_bb0350","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: a stressful review","volume":"55","author":"Reichmann","year":"2016","journal-title":"Neuropeptides"},{"issue":"12","key":"10.1016\/j.npep.2026.102605_bb0355","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1523\/JNEUROSCI.4056-03.2004","article-title":"Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus","volume":"24","author":"Richichi","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.npep.2026.102605_bb0360","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jnc.13347","article-title":"Locus coeruleus response to single-prolonged stress and early intervention with intranasal neuropeptide Y","volume":"135","author":"Sabban","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.npep.2026.102605_bb0365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npep.2015.11.004","article-title":"Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder","volume":"56","author":"Sabban","year":"2016","journal-title":"Neuropeptides"},{"issue":"11","key":"10.1016\/j.npep.2026.102605_bb0370","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13279","article-title":"Potential benefits of intranasal neuropeptide Y include sustained extinction of fear memory","volume":"35","author":"Sabban","year":"2023","journal-title":"J. Neuroendocrinol."},{"issue":"6","key":"10.1016\/j.npep.2026.102605_bb0375","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/mp.2012.101","article-title":"Neuropeptide Y and posttraumatic stress disorder","volume":"18","author":"Sah","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.npep.2026.102605_bb0380","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.biopsych.2009.04.037","article-title":"Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder","volume":"66","author":"Sah","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2026.102605_bb0385","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.psyneuen.2013.10.017","article-title":"Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder","volume":"40","author":"Sah","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1016\/j.npep.2026.102605_bb0390","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1017\/S1461145714000054","article-title":"Effects of histone deacetylase inhibitors on amygdaloid histone acetylation and neuropeptide Y expression: a role in anxiety-like and alcohol-drinking behaviors","volume":"17","author":"Sakharkar","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12993-024-00230-5","article-title":"Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions","volume":"20","author":"S\u00e1nchez-Varo","year":"2024","journal-title":"Behav. Brain Funct."},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0400","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ijnp\/pyx109","article-title":"A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder","volume":"21","author":"Sayed","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Pt B","key":"10.1016\/j.npep.2026.102605_bb0405","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.expneurol.2016.06.020","article-title":"Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): A translational update","volume":"284","author":"Schmeltzer","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.npep.2026.102605_bb0410","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuroscience.2013.01.040","article-title":"Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats","volume":"236","author":"Serova","year":"2013","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0415","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euroneuro.2013.11.007","article-title":"Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model","volume":"24","author":"Serova","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0420","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2019.02.010","article-title":"Single prolonged stress PTSD model triggers progressive severity of anxiety, altered gene expression in locus coeruleus and hypothalamus and effected sensitivity to NPY","volume":"29","author":"Serova","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0425","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1568007054546153","article-title":"The putative neuroprotective role of neuropeptide Y in the central nervous system","volume":"4","author":"Silva","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.npep.2026.102605_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2025.102538","article-title":"Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: perceptions into treatment-resistant depression","volume":"112","author":"Singanwad","year":"2025","journal-title":"Neuropeptides"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0435","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu023","article-title":"Cerebrospinal fluid neuropeptide Y levels in major depression and reported childhood trauma","volume":"18","author":"Soleimani","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"17","key":"10.1016\/j.npep.2026.102605_bb0440","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1073\/pnas.1017719108","article-title":"Tonic inhibition of chronic pain by neuropeptide Y","volume":"108","author":"Solway","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0445","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1074\/jbc.M115.678185","article-title":"Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer\u2019s disease","volume":"291","author":"Spencer","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"5858","key":"10.1016\/j.npep.2026.102605_bb0450","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/296659a0","article-title":"Neuropeptide Y\u2013a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide","volume":"296","author":"Tatemoto","year":"1982","journal-title":"Nature"},{"issue":"6709","key":"10.1016\/j.npep.2026.102605_bb0455","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/24614","article-title":"Ethanol consumption and resistance are inversely related to neuropeptide Y levels","volume":"396","author":"Thiele","year":"1998","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.npep.2026.102605_bb0460","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/00003088-200140120-00003","article-title":"Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations","volume":"40","author":"Thorne","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20132","key":"10.1016\/j.npep.2026.102605_bb0465","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.npep.2026.102605_bb0470","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2017.00178","article-title":"Neuropeptide Y in alcohol addiction and affective disorders","volume":"8","author":"Thorsell","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"23","key":"10.1016\/j.npep.2026.102605_bb0475","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1073\/pnas.220232997","article-title":"Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression","volume":"97","author":"Thorsell","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0480","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.npep.2009.05.003","article-title":"Involvement of neuropeptide Y in the acute, chronic and withdrawal responses of morphine in nociception in neuropathic rats: behavioral and neuroanatomical correlates","volume":"43","author":"Upadhya","year":"2009","journal-title":"Neuropeptides"},{"issue":"3","key":"10.1016\/j.npep.2026.102605_bb0485","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.npep.2026.102605_bb0490","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nm0797-761","article-title":"Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors","volume":"3","author":"Woldbye","year":"1997","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.npep.2026.102605_bb0495","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14728222.2011.628314","article-title":"Central functions of neuropeptide Y in mood and anxiety disorders","volume":"15","author":"Wu","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.npep.2026.102605_bb0500","first-page":"R484","article-title":"Intranasal administration of neuropeptide Y significantly antagonized stress-induced colonic dysmotility via central GABA(A) receptors in male rats","volume":"323","author":"Yang","year":"2022","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"issue":"7","key":"10.1016\/j.npep.2026.102605_bb0505","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.biopsych.2005.08.027","article-title":"Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping","volume":"59","author":"Yehuda","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.npep.2026.102605_bb0510","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13311-019-00758-9","article-title":"Intranasal neuropeptide Y Blunts Lipopolysaccharide-Evoked Sickness behavior but not the immune response in mice","volume":"16","author":"Zenz","year":"2019","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.npep.2026.102605_bb0515","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13578-021-00657-7","article-title":"Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review","volume":"11","author":"Zhang","year":"2021","journal-title":"Cell Biosci."},{"issue":"7190","key":"10.1016\/j.npep.2026.102605_bb0520","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nature06858","article-title":"Genetic variation in human NPY expression affects stress response and emotion","volume":"452","author":"Zhou","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.npep.2026.102605_bb0525","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1176\/appi.ajp.158.11.1923","article-title":"Gender differences in patients with posttraumatic stress disorder in a general psychiatric practice","volume":"158","author":"Zlotnick","year":"2001","journal-title":"Am. J. Psychiatry"}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417926000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417926000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:26:42Z","timestamp":1785173202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417926000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":105,"alternative-id":["S0143417926000211"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2026.102605","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisited case for intranasal neuropeptide Y based therapeutics: From preclinical to clinical","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2026.102605","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102605"}}